Likewise, a recombinant IL-2, which includes a tumor-targeting antibody (Ab) and a super mutant IL-2 (sumIL-2), referred to as Ab-sumIL2, substantially boosts antitumor efficacy by precisely targeting tumors and binding specifically to cytotoxic T lymphocytes (CTLs) [33]. In our study, the triple therapy regimen, which includes XRT, Anti-PD1, and RDB 1462, exhibited a remarkable suppression of tumor growth. The gene discussed is IL2; the disease is neoplasm.